publication date: Feb. 28, 2017

Thyroid Cancer Pitt Study Finds Potential Marker of Drug Response in Many Cancer Types

Researchers at the University of Pittsburgh School of Medicine have uncovered a novel genetic mechanism of thyroid cancer, as well as a marker that may predict response to a particular class of drugs, not just in patients with thyroid cancer, but in those with many other types of cancer as well.

The new findings were published in Proceedings of the National Academy of Science.

“These results further our understanding of the biology of thyroid cancer. More broadly, they also suggest a potential treatment strategy for many different types of cancer,” explained lead study author Yuri Nikiforov, professor of pathology, vice chair for molecular pathology and director of UPMC’s Division of Molecular & Genomic Pathology.

To identify new genetic abnormalities associated with thyroid cancer, Nikiforov and his team applied a powerful technology called next-generation sequencing to analyze a series of papillary thyroid carcinomas (the most common form of thyroid cancer) that did not contain any of the known mutations.

The researchers found that a significant proportion of these tumors had a complex genetic alteration involving fusion of a gene named THADA to a previously unknown region near a gene called IGF2BP3. The result of this gene fusion was elevated levels of IGF2BP3 protein, an important component of the IGF1R … Continue reading CCL Feb 2017 – Pitt Study Finds Potential Marker of Drug Response in Many Cancer Types

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.